Tag Archives: Wyeth

The High Cost of Staying Lean

It’s annual meeting time for Big Pharma — and trimming the fat to deliver more bacon to shareholders is the C suite’s preferred plat du jour. But taking costs out of the business can carry a staggering special supplement charge to the menu, with far more at stake than the economizing equivalent of that McDonald’s […]
Posted in Strategy | Also tagged , , , , | Leave a comment

AstraZeneca, BMS Announce Layoffs and Buyouts

AstraZeneca was the topic of conversation this week as word broke that the company is offering buyout deals to every member of its 5,500 US sales force. “AstraZeneca is making changes to our sales force, which will be managed first by looking at vacancies and offering field sales employees the opportunity to self-identify whether they […]
Posted in Strategy | Also tagged , , , , , , , | 1 Comment

Avastin Gets Green Light for Use in Kidney Cancer

Image by Getty Images via Daylife Score another win for Genentech and its cancer treatment Avastin (bevacizumab). On Monday, the biotech giant, now owned entirely by Roche, announced that FDA has approved the drug for kidney cancer. Avastin blocks new blood vessels from forming and supplying tumors with the nutrients they need to grow and […]
Posted in News | Also tagged , , , , , , | Leave a comment

March Issue of Pharm Exec Online Now

The March issue of Pharmaceutical Executive Magazine is online and in the mail as we speak. The new issue features insights into the Pfizer/Wyeth merger, our annual media audit, a look at the new sales force model, and the 2009 Ad Stars. Click here to check it out. The March issues also comes with the […]
Posted in Pharm Exec Magazine | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta